The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO Asia 2023 | Tyrosine kinase inhibitors in EGFR-mutant NSCLC: when and who?
Masahiro Tsuboi, MD, National Cancer Center Hospital East, Chiba, Japan, discusses when and to whom to administer tyrosine kinase inhibitor (TKI) treatment. The NEJ009 study (NCT04035486) showed getfitinib plus chemotherapy prolonged survival and improved overall response rate in comparison to gefitinib alone. Likewise, FLAURA-2 (NCT04035486) has shown osimertinib to be more efficacious when administered with chemotherapy. Testing osimertinib specifically in the neoadjuvant setting, Dr Tsuboi is eager for the results of NeoADAURA (NCT04351555) to further the understanding of TKI and chemotherapy’s temporal relationship. Dr Tsuboi addresses patient selection and states liquid biopsy could be of use in identifying patients who could benefit. This interview took place at the European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
